Summary: Minimal evidence exists linking CACNA1C as a pharmacogenomic marker, and CACNA1C shows little clinical utility as a disease marker. While there is an association between CACNA1C and bipolar disorder and schizophrenia, the absolute contribution of CACNA1C to disease risk is very small. Therefore, genetic testing for CACNA1C is not recommended at this time.

What is CACNA1C?
CACNA1C encodes the α-1C subunit of the voltage-gated L-type Ca2+ channel, which plays a critical role in neurotransmission, gene expression, synaptic plasticity, and memory processes in the brain.1-7 While CACNA1C has been studied as a potential disease marker for schizophrenia (SCZ), bipolar disorder (BPD), and major depressive disorder (MDD), concrete evidence is lacking to associate genetic variation in CACNA1C with psychiatric medication response.

Is CACNA1C a risk factor for bipolar disorder, schizophrenia, and major depressive disorder?
Single nucleotide polymorphisms (SNPs) within CACNA1C repeatedly reached genome-wide significance (p<5 x 10-8) for an association with SCZ or BPD.8-14 However, the effect size is small (OR = 1.07-1.18), and CACNA1C is only one of many susceptibility genes that impact the risk for these disorders. Some of the other genes associated with SCZ and BPD include ANK3, TRANK1, ODZ4, and MHC.13, 15, 16 Additionally, CACNA1C has been linked to MDD, but these results are less consistent.17

What do the data say about CACNA1C variation and psychiatric treatment response?
There are currently only four studies that have evaluated the effect of CACNA1C variants on response to psychiatric medications. One study found two SNPs (rs1006737 and rs10848635) were associated with an increased risk of suicidality and worsening of concentration among Caucasians taking citalopram. However, there was no association between CACNA1C genotype and treatment response or rates of remission.18 A second study that evaluated response to antidepressants found that the risk allele of rs1006737 was associated with better treatment response and rate of remission in one European group (n = 357), but the same allele was associated with an increased rate of treatment-resistant depression in a second European group (n = 218). No associations were found in a third group of Italian ancestry (n = 96).19 In another study that evaluated response to olanzapine in a Korean population (n = 502), five novel SNPs were associated with improvement of SCZ symptoms in the Positive and Negative Syndrome Scale (PANSS) subscales. However, rs1006737 was found to have no association with treatment and total PANSS score improvements.20 Lastly, in a Han Chinese population, another polymorphism in CACNA1C (rs2239063) was associated with better treatment response in SCZ patients treated with olanzapine for 6 weeks (n = 884). There were no associations with treatment response and other antipsychotics (n = 2,908).21

What is the clinical significance of CACNA1C genotyping?
The actual level of risk conferred by CACNA1C variants is very small. For example, a recent meta-analysis in SCZ determined the odds ratio for a common SNP (rs1006737) to be 1.20 in an Asian population.22 Based on this data, a pooled relative risk was calculated to be 1.10. Therefore, given a lifetime prevalence of SCZ being ~0.60% 23-26, carriers would be expected to have a 0.64% risk of lifetime SCZ diagnosis, compared to a 0.58% risk for non-carriers.27 In effect, the CACNA1C variant confers a 0.06% absolute increase in the risk of developing SCZ. Thus, while the diagnostic association appears to be consistent, the absolute contribution of CACNA1C to disease risk is very small, and CACNA1C is only one of many susceptibility genes. Without a proper understanding of the modest clinical impact of CACNA1C variation, testing for CACNA1C may lead to overestimation of disease risk, unnecessary use of psychotropic medications, and undue patient anxiety regarding the development of serious conditions. Furthermore, the limited studies investigating the effect of CACNA1C variants on psychiatric treatment response have not produced any consistent findings. Additional well-designed, independently replicated pharmacogenomic studies are needed to verify whether CACNA1C variation predicts response to psychiatric medications. While CACNA1C remains an intriguing research target, genetic testing for CACNA1C is not recommended at this time.


  1. Ban TA, Morey L, Aguglia E et al. Nimodipine in the treatment of old age dementias. Prog Neuropsychopharmacol Biol Psychiatry.
  2. Trompet S, Westendorp RG, Kamper AM et al. Use of calcium antagonists and cognitive decline in old age. The Leiden 85-plus study.
    Neurobiol Aging. 2008;29:306-308. DOI: 10.1016/j.neurobiolaging.2006.10.006
  3. Deyo RA, Straube KT, Disterhoft JF. Nimodipine facilitates associative learning in aging rabbits. Science. 1989;243:809-811.
  4. Levy A, Kong RM, Stillman MJ et al. Nimodipine improves spatial working memory and elevates hippocampal acetylcholine in young rats.
    Pharmacol Biochem Behav. 1991;39:781-786.
  5. Bito H, Deisseroth K, Tsien RW. CREB phosphorylation and dephosphorylation: a Ca(2+)- and stimulus duration-dependent switch for
    hippocampal gene expression. Cell. 1996;87:1203-1214.
  6. Dolmetsch RE, Pajvani U, Fife K et al. Signaling to the nucleus by an L-type calcium channel-calmodulin complex through the MAP kinase
    pathway. Science. 2001;294:333-339. DOI: 10.1126/science.1063395
  7. Sinnegger-Brauns MJ, Huber IG, Koschak A et al. Expression and 1,4-dihydropyridine-binding properties of brain L-type calcium channel
    isoforms. Mol Pharmacol. 2009;75:407-414. DOI: 10.1124/mol.108.049981
  8. Ferreira MA, O’Donovan MC, Meng YA et al. Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1C in
    bipolar disorder. Nat Genet. 2008;40:1056-1058. DOI: 10.1038/ng.209
  9. Cross-Disorder Group of the Psychiatric Genomics C. Identification of risk loci with shared effects on five major psychiatric disorders: a
    genome-wide analysis. Lancet. 2013;381:1371-1379. DOI: 10.1016/S0140-6736(12)62129-1
  10. Bergen SE, O’Dushlaine CT, Ripke S et al. Genome-wide association study in a Swedish population yields support for greater CNV and MHC
    involvement in schizophrenia compared with bipolar disorder. Mol Psychiatry. 2012;17:880-886. DOI: 10.1038/mp.2012.73
  11. Ripke S, O’Dushlaine C, Chambert K et al. Genome-wide association analysis identifies 13 new risk loci for schizophrenia. Nat Genet.
    2013;45:1150-1159. DOI: 10.1038/ng.2742
  12. Schizophrenia Working Group of the Psychiatric Genomics C. Biological insights from 108 schizophrenia-associated genetic loci. Nature.
    2014;511:421-427. DOI: 10.1038/nature13595
  13. Ruderfer DM, Fanous AH, Ripke S et al. Polygenic dissection of diagnosis and clinical dimensions of bipolar disorder and schizophrenia. Mol
    Psychiatry. 2014;19:1017-1024. DOI: 10.1038/mp.2013.138
  14. Psychiatric GCBDWG. Large-scale genome-wide association analysis of bipolar disorder identifies a new susceptibility locus near ODZ4.
    Nat Genet. 2011;43:977-983. DOI: 10.1038/ng.943
  15. Chen DT, Jiang X, Akula N et al. Genome-wide association study meta-analysis of European and Asian-ancestry samples identifies three
    novel loci associated with bipolar disorder. Mol Psychiatry. 2013;18:195-205. DOI: 10.1038/mp.2011.157
  16. Muhleisen TW, Leber M, Schulze TG et al. Genome-wide association study reveals two new risk loci for bipolar disorder. Nat Commun.
    2014;5:3339. DOI: 10.1038/ncomms4339
  17. Green EK, Grozeva D, Jones I et al. The bipolar disorder risk allele at CACNA1C also confers risk of recurrent major depression and of
    schizophrenia. Mol Psychiatry. 2010;15:1016-1022. DOI: 10.1038/mp.2009.49
  18. Casamassima F, Huang J, Fava M et al. Phenotypic effects of a bipolar liability gene among individuals with major depressive disorder. Am J
    Med Genet B Neuropsychiatr Genet. 2010;153B:303-309. DOI: 10.1002/ajmg.b.30962
  19. Fabbri C, Corponi F, Albani D et al. Pleiotropic genes in psychiatry: Calcium channels and the stress-related FKBP5 gene in antidepressant
    resistance. Prog Neuropsychopharmacol Biol Psychiatry. 2018;81:203-210. DOI: 10.1016/j.pnpbp.2017.10.005
  20. Porcelli S, Lee SJ, Han C et al. CACNA1C gene and schizophrenia: a case-control and pharmacogenetic study. Psychiatr Genet. 2015;25:163-
    167. DOI: 10.1097/YPG.0000000000000092
  21. Yu H, Yan H, Wang L et al. Five novel loci associated with antipsychotic treatment response in patients with schizophrenia: a genome-wide
    association study. Lancet Psychiatry. 2018. DOI: 10.1016/S2215-0366(18)30049-X
  22. Jiang H, Qiao F, Li Z et al. Evaluating the association between CACNA1C rs1006737 and schizophrenia risk: A meta-analysis. Asia Pac
    Psychiatry. 2015;7:260-267. DOI: 10.1111/appy.12173
  23. Reeves WC, Strine TW, Pratt LA et al. Mental illness surveillance among adults in the United States. MMWR Suppl. 2011;60:1-29.
  24. McGrath J, Saha S, Chant D et al. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev. 2008;30:67-76.
    DOI: 10.1093/epirev/mxn001
  25. Goldner EM, Hsu L, Waraich P et al. Prevalence and incidence studies of schizophrenic disorders: a systematic review of the literature. Can J
    Psychiatry. 2002;47:833-843. DOI: 10.1177/070674370204700904
  26. NIMH. Statistics-Schizophrenia. (last accessed March 1, 2018).
  27. Wang Z. Converting Odds Ratio to Relative Risk in Cohort Studies with Partial Data Information. Journal of Statistical Software. 2013;55:1-11.